Dept. of the Army Prototype Development to Combat Novel Coronavirus Disease COVID-19The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). Deadline: April 15, 2020 View details
Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Amendments
Note: COVID-19 response related Areas of Interest includes:
- AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
- AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
- AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- AOI 8.3 COVID-19 Vaccine
- AOI 9.2 COVID-19 Therapeutics
- AOI 9.3 Immunomodulators or therapeutics targeting lung repair
- AOI 9.5 Pre-exposure and post-exposure prophylaxis
- AOI 10 Respiratory protective devices
- AOI 11 Ventilators
- AOI 17 Advanced Manufacturing Technologies
Deadline: October 31, 2020
Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. No deadline View details
RFA-AI-20-028 — Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant. Letter of intent deadline: May 29, 2020 View Details
Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)
The National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore howto model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
DOE Dear Colleague Letter: Coronavirus Disease 2019 (COVID-19)
DOE provides research funding and resources to National Laboratories and academic institutions for a broad range of scientific disciplines including genomic-related research, structural characterization of biomolecules and computational modelling of biological systems.
These areas of research support the development of new technologies, generation of datasets, and computational technologies for data synthesis, analysis and visualization as part of DOE’s energy-related missions but are also available to the scientific community and the public to facilitate research and development of vaccines, therapeutics, and diagnostics for infectious diseases, including those caused by coronaviruses.
Centers for Disease Control (CDC) COVID-19 Broad Agency Announcement
This BAA is open and in effect for 14 days from the date of issuance (March 11, 2020 through March 25, 2020). THIS IS AN IMMEDIATE CALL FOR WHITE PAPERS. Prior to submission of a white paper, offerors are strongly encouraged to contact the CDC BAA technical point of contact for the research topic/subtopic of interest.
White papers must be received electronically by 3:00PM EST on March 25, 2020 in order to be considered for further evaluation. White papers should be submitted electronically to Jan Gum at firstname.lastname@example.org.
2020 NIAID Omnibus Broad Agency Announcement
Deadlines specific to research areas. See link below.
NIH Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.
NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
Applications will be accepted on a rolling basis from February 6, 2020 through February 6, 2021 by 5:00 PM local time of the applicant organization.
NIH Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
Deadline: June 29, 2020 (Letter of intent due 30 days prior)
NIH Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.
Deadline: September 9, 2020
Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)
Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
XSEDE COVID-19 HPC Consortium
Bringing together the Federal government, industry, and academic leaders to provide access to the world’s most powerful high-performance computing resources in support of COVID-19 research.